COVID-19 and COPD: a narrative review of the basic science and clinical outcomes
The 2019 coronavirus disease (COVID-19) pandemic is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Clinical outcomes, including mortality, are worse in males, older individuals and patients with comorbidities. COPD patients are included in shielding strategies due to their susceptibility to virus-induced exacerbations, compromised pulmonary function and high prevalence of associated comorbidities. Using evidence from basic science and cohort studies, this review addresses key questions concerning COVID-19 and COPD. First, are there mechanisms by which COPD patients are more susceptible to SARS-CoV-2 infection? Secondly, do inhaled corticosteroids offer protection against COVID-19? And, thirdly, what is the evidence regarding clinical outcomes from COVID-19 in COPD patients? This up-to-date review tackles some of the key issues which have significant impact on the long-term outlook for COPD patients in the context of COVID-19..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
---|---|
Enthalten in: |
European Respiratory Review - 29(2020), 158 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Andrew Higham [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
---|
doi: |
10.1183/16000617.0199-2020 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ072787376 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ072787376 | ||
003 | DE-627 | ||
005 | 20230309111756.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230228s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1183/16000617.0199-2020 |2 doi | |
035 | |a (DE-627)DOAJ072787376 | ||
035 | |a (DE-599)DOAJ8482c72645fc46c2934f1bf7ab638ef0 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC705-779 | |
100 | 0 | |a Andrew Higham |e verfasserin |4 aut | |
245 | 1 | 0 | |a COVID-19 and COPD: a narrative review of the basic science and clinical outcomes |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a The 2019 coronavirus disease (COVID-19) pandemic is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Clinical outcomes, including mortality, are worse in males, older individuals and patients with comorbidities. COPD patients are included in shielding strategies due to their susceptibility to virus-induced exacerbations, compromised pulmonary function and high prevalence of associated comorbidities. Using evidence from basic science and cohort studies, this review addresses key questions concerning COVID-19 and COPD. First, are there mechanisms by which COPD patients are more susceptible to SARS-CoV-2 infection? Secondly, do inhaled corticosteroids offer protection against COVID-19? And, thirdly, what is the evidence regarding clinical outcomes from COVID-19 in COPD patients? This up-to-date review tackles some of the key issues which have significant impact on the long-term outlook for COPD patients in the context of COVID-19. | ||
653 | 0 | |a Diseases of the respiratory system | |
700 | 0 | |a Alexander Mathioudakis |e verfasserin |4 aut | |
700 | 0 | |a Jørgen Vestbo |e verfasserin |4 aut | |
700 | 0 | |a Dave Singh |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t European Respiratory Review |d European Respiratory Society, 2009 |g 29(2020), 158 |w (DE-627)DOAJ000028703 |x 16000617 |7 nnns |
773 | 1 | 8 | |g volume:29 |g year:2020 |g number:158 |
856 | 4 | 0 | |u https://doi.org/10.1183/16000617.0199-2020 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/8482c72645fc46c2934f1bf7ab638ef0 |z kostenfrei |
856 | 4 | 0 | |u http://err.ersjournals.com/content/29/158/200199.full |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/0905-9180 |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1600-0617 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
951 | |a AR | ||
952 | |d 29 |j 2020 |e 158 |